

# Lymphoma Committee

## Leadership

Chair: .....Jonathan W. Friedberg, MD  
 Vice-Chair: ..... Sonali M. Smith, MD  
 Executive Officer: .....Susan M. O'Brien, MD  
 Statisticians: .....Michael LeBlanc, PhD  
 ..... Hongli Li, MS

## Scientific Leadership

Translational Medicine: ..... Alexey Danilov, MD, PhD  
 Radiation Oncology: ..... Louis S. Constine, MD  
 Imaging: ..... Lawrence H. Schwartz, MD  
 Pathology: ..... Joo Y. Song, MD  
 Early Therapeutics: ..... Nasheed Mohammad Hossain, MD

## Designates

Cancer Control: .....Hayder Saeed, MD  
 Digital Engagement: ..... Mazyar Shadman, MD  
 Veterans Affairs: ..... Helen Ma, MD  
 Data Coordinators: ..... Iris Syquia  
 ..... Gabi Herbert  
 Oncology Research Professionals:  
 CRA: ..... Erin M. Cebula, MPH  
 Nurse: ..... Molly Beth Adamek, BSN, RN  
 Patient Advocate: ..... Hildy Dillon, MPH  
 Pharmaceutical Science: ..... Holly O. Chan, PharmD  
 ..... Martina Fraga, PharmD  
 Protocol Project Manager: ..... Katarina Gasic  
 Clinical Trials Program Manager: ..... TBD

## Time/Location

Friday, October 21, 2022 9:00 am - 11:00 am  
 Room: Crystal A (Lobby Level, West Tower)

## Agenda

**9:00 - 9:05 am**     **Welcome** - Jonathan Friedberg and Sonali Smith

**9:05 - 9:45 am**     **Mini-symposium: The pursuit of equity and inclusion in lymphoma careers** - Sonali Smith, Elwood V. Jensen Professor, Chief, Hematology/Oncology Section, University of Chicago

**9:45 - 10:45 am**     **Spotlight on studies pending activation**  
 S2114 DLBCL post CAR-T cell therapy     Dr. Hess  
 COG Early stage Hodgkin lymphoma     Dr. Hu

**10:50 - 11:55 am**     **Ongoing Studies**  
 S1826: Dr. Herrera  
 S1918: Dr. Brem

S1608: Dr. Barr  
 A051902: Dr. Amengual  
 ANHL1931: Dr. Kamdar  
 EA4151: Dr. Till  
 EA4181: Dr. Spurgeon  
 S1925 (CLL): Dr. Stephens  
 A051301: Dr. Stiff

**11:55 - 12:00 pm**     **Other Business/Concluding Remarks**

## Proposed Studies

**S2114**, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain.

**S2207**, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual and Reagan.

## Active Studies

**S1826**, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera and Friedberg. Activated: 7/19/19.

**S1608**, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Temporarily closed: 02/09/2022.

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

**CTSU/A051301**, "A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype." Drs. Andreadis. SWOG Champion: Dr. Stiff. Activated: 7/6/16.

**CTSU/A051701**, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Temporarily closed: 8/2/21.

# Lymphoma Committee

**CTSU/EA4151**, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission. Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

**CTSU/EA4181**, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 years Old with Untreated Mantle Cell Lymphoma. Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19.

**CTSU/ANHL1931**, "A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." SWOG Champion: Dr. Kamdar. SWOG Champion: Dr. Manali. Activated 6/7/2021.

**CTSU/A051902**, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Neha Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

## Open Leukemia Studies

**S1925**, A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study. Dr. Stephens. Activated: 12/14/20.

**S1905**, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Re-lapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

**A041702**, "A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients ( $\geq$  65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)." Dr. Woyach. SWOG Champion: Dr. Hill. Activated: 1/4/19.

## Open Rare Cancers Study

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Drs. Chen, Flaherty, Conley, et al. Activated: 8/12/15.

## Open Cancer Care Delivery Study

**S1912CD**, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

## Lymphoma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1608	S1826	S1918	A051301	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	1	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	1	-	-	-	-
Boston Medical Center	-	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	11	11
Cancer Research Consortium of West Michigan NCORP	3	13	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	4	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	2	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	3	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	8	20	2	1	-	-	17	-
Columbia University Minority Underserved NCORP	-	1	2	-	-	1	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	3	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	13	-
Georgia Cares Minority Underserved NCORP	-	5	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	17	-	-	-	-	-	-
Henry Ford Hospital	-	7	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	2	10	-	-	-	11	-	9
King Faisal Specialist Hospital and Research Centre	-	-	-	4	-	-	-	-
Loyola University Medical Center	-	8	-	-	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	2	17	1	-	-	-	2	-
Michigan Cancer Research Consortium NCORP	1	5	2	-	-	-	-	-
Moffitt Cancer Center	-	15	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	-	2	-

## Lymphoma Committee

Accrual from trial opening through 6/30/2022 by Institution and Study

	S1608	S1826	S1918	A051301	ANHL1931	E4412	EA4151	EA4181
Nevada Cancer Research Foundation NCORP	-	2	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	4	-	-	-	-	5	5
Pacific Cancer Research Consortium NCORP	-	5	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	5	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	15	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	-	-	1	-	-	-
UC San Diego Moores Cancer Center	-	8	-	-	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	11	-	-	-	7	5	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	6	-	-	-	-	2	2
University of Colorado Cancer Center LAPS	-	3	-	1	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	1
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-
University of Rochester LAPS	13	30	-	3	-	-	10	17
University of Texas Health Science Center at San Antonio	-	16	-	-	-	-	11	-
University of Texas MD Anderson Cancer Center LAPS	3	29	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	14	1	-	-	-	14	11
Upstate Carolina Consortium Community Oncology Research Program	1	7	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	3	-	1	-	-	1	6
Wisconsin NCI Community Oncology Research Program	-	9	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	6	-	-	-	-	4	-
ALLIANCE	15	119	18	-	-	-	-	-
CCTG	-	20	-	-	-	-	-	-
COG	-	288	-	-	-	-	-	-
ECOG-ACRIN	5	77	5	-	-	-	-	-
NRG	11	44	2	-	-	-	-	-
<b>Total</b>	<b>72</b>	<b>893</b>	<b>35</b>	<b>12</b>	<b>1</b>	<b>20</b>	<b>103</b>	<b>64</b>